Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, recently announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).
Details of the presentation are as follows:
|Friday January 26, 2018||From 3:03 to 3:15pm CET||
Selected Oral Communications Session
For more information, visit www.journeessfnp.fr/programme.